Introduction {#s1}
============

Asthma is a chronic immunological disorder of lung characterized by reversible airway obstruction, airway inflammation and increased airway hyperresponsiveness in response to provocative challenge. Physiological changes of the disease include the accumulation of inflammatory cells, especially the eosinophils, goblet cell metaplasia of lung epithelium with a mucus secreting phenotype (Laitinen et al., [@B27]). The worldwide incidence rate of asthma has been estimated to be 2.65 to 4/1000 per year and is more common among children with age less than 5 years where it ranges from 8.1 to 14/1000 per year (Gergen and Weiss, [@B14]). This case study also says that according to report presented by National Health and Nutrition Examination Survey (NHANES-2), this prevalence is higher in African-Americans (12.27) than in Caucasian (10.47) respectively. In Asia, adult asthma prevalence rate ranges from 3.6% in Hongkong, 2.4% in India, 0.1% in Singapore, 2.4% in Taiwan, and 2.91% in Thailand (Subbarao et al., [@B49]). Thus, asthma is arguably a major health problem worldwide deteriorating the quality of life of individuals affected and places a burden on their family and even the society. Indirect losses are due to disability, absenteeism and health care management. Focus of the present asthma biomarkers has been in the risk assessment before diagnosis, to determine the stage, grade of the disease during diagnosis and monitoring therapy or recurrent disease in the later stage of treatment. The biomolecules that undergo cellular, biochemical or molecular alterations in asthma patients vs. healthy subjects that are measurable in biological samples such as Broncho alveolar lavage Fluid (BALF), Nasal lavage fluid (NLF), blood or lung tissues may be considered as asthma biomarkers. These biomarkers are used for disease diagnosis and prognosis. A few native proteins that are targets for "hit" by a drug to achieve desirable therapeutic effects are another class of biomolecules which are known as "drug targets." There has been a continuous quest for developing diagnostic biomarker to differentiate "allergic asthma" from other pulmonary inflammations and also to develop more biologic drugs by targeting biomolecules playing a key role in regulating asthma pathogenesis which may be more effective than traditional chemical drugs such as steroids (Murugan et al., [@B39]). Current research is focused on identifying key regulators and molecular pathways, which are associated in asthma pathogenesis. Systems approaches including genomics, proteomics, epigenomics and further integrating these attempts provide deeper understanding of the disease prognosis (Strimbu and Tavel, [@B48]). In this mini review, we gave a brief overview of different systems level approaches studied related to asthma biomarkers and we further focused on pathways, biological processes and molecular functions of these classes of biomarkers.

Molecular biomarkers in allergic asthma
=======================================

Genomic approach
----------------

Genomic studies have reported large number of candidate biomarkers through both high and low throughput techniques. Experiments were done on human, mouse, monkey and rat model systems by comparing the expression of genes through challenging them with inhalant allergens and monitoring at different time intervals or by using resistant and susceptible strains of animals. Microarray based experiments reported hundreds of differentially expressed genes and hence plethora of information. Different samples like bronchial epithelial cells, eosinophils, CD4+ T-cells, mouse lung tissues have been employed in the experimental designs. The genes which showed significant differential expression were found to be linked with airway remodeling, production of mucus, macrophages and shifting the immune response toward Th2 phenotype thus enhancing asthma exacerbation (Laprise et al., [@B28]; Woodruff et al., [@B56]; Siddiqui et al., [@B47]). In most microarray experiments the differentially expressed genes were further validated either by RT-PCR or western blot. Genome Wide Association Study and Candidate gene approach have identified several regions on human chromosome which are linked to asthma phenotype. Nucleotide substitution in promoter region and ORF of IL4 receptor, IL13, HLA-II alleles, RANTES and CC-chemokine ligands were found to be strongly associated with asthma (Toda and Ono, [@B52]). We have compiled fifteen biomarkers from Database of Allergy and Asthma Biomarkers (DAAB)[^1^](#fn0001){ref-type="fn"} having more than two citations and listed in Table [1](#T1){ref-type="table"}, out of which 11 were obtained from genomics.

###### 

**List of asthma biomarkers cited in two or more times in Database of Allergy and Asthma Biomarkers (DAAB)**.

  **Gene Symbol**                      **Name of the genes/proteins**          **Sample**                                            **Organism**   **Approach**   **References**
  ------------------------------------ --------------------------------------- ----------------------------------------------------- -------------- -------------- ----------------------------------
  ARG1                                 Arginase 1                              BAL macrophages, BAL Fluid                            Mouse, human   G^HL^, P^HL^   Siddiqui et al., [@B47] \[G^H^\]
  Wu et al., [@B57] \[P^H^\]                                                                                                                                       
  Torrone et al., [@B53] \[P^H^                                                                                                                                    
  Cloots et al., [@B6] \[G^L^\]                                                                                                                                    
  North et al., [@B40] \[P^L^\]                                                                                                                                    
  BPIFA1                               Palate lung nasal epithelial clone      BALFluid and nasal lavage fluid                       Human          P^HL^          Wu et al., [@B57] \[P^H^\]
  Ghafouri et al., [@B15] \[P^H^\]                                                                                                                                 
  Chu et al., [@B5] \[P^L^\]                                                                                                                                       
  CPA3                                 Carboxypeptidase A3                     Airway epithelial cells, bronchoscopy tissue sample   Human, mouse   G^HL^          Woodruff et al., [@B56] \[G^H^\]
  Laprise et al., [@B28] \[G^H^\]                                                                                                                                  
  Balzar et al., [@B1] \[G^L^\]                                                                                                                                    
  CCL8                                 Chemokine (C-C motif) ligand 8          Left lung tissue, BAL macrophages                     Mouse          G^HL^          Park et al., [@B42] \[G^H^\]
  Siddiqui et al., [@B47] \[G^H^\]                                                                                                                                 
  Fu et al., [@B12] \[G^L^\]                                                                                                                                       
  Chi3l3                               Chitinase 3-like3                       BALFluid                                              Mouse          P^HL^          Greenlee et al., [@B17] \[P^H^\]
  Zhao et al., [@B58] \[P^H^\]                                                                                                                                     
  Louten et al., [@B31] \[P^L^\]                                                                                                                                   
  Chi3l4                               Chitinase 3-like 4                      BAL macrophages, BAL Fluid,                           Human, mouse   G^HL^, P^HL^   Siddiqui et al., [@B47] \[G^H^\]
  Webb et al., [@B55] \[G^L^\]                                                                                                                                     
  Greenlee et al., [@B17] \[P^H^\]                                                                                                                                 
  Zhao et al., [@B58] \[P^H^\]                                                                                                                                     
  Louten et al., [@B31] \[P^L^\]                                                                                                                                   
  CLCA3                                Calcium activated chloride channel -3   Airway epithelial cells, left lung tissue             Mouse          G^HL^          Woodruff et al., [@B56] \[G^H^\]
  Park et al., [@B42] \[G^H^\]                                                                                                                                     
  Zhou et al., [@B59] \[G^L^\]                                                                                                                                     
  Cxcl15                               Chemokine (C-X-C motif) ligand 15       BAL Fluid                                             Mouse          P^H^           Greenlee et al., [@B17] \[P^H^\]
  Zhao et al., [@B58] \[P^H^\]                                                                                                                                     
  IL10                                 Interleukin 10                          Lung tissue, CD4+T Cell                               Mouse, human   rG^HL^         López et al., [@B30] \[G^H^\]
  Hansel et al., [@B19] \[G^H^\]                                                                                                                                   
  Lyon et al., [@B35] \[G^L^\]                                                                                                                                     
  IL13                                 Interleukin 13                          CD4+T Cell,                                           Human          G^HL^, E^L^    Hansel et al., [@B19] \[G^H^\]
  Durham et al., [@B11] \[G^H^\]                                                                                                                                   
  Kanoh et al., [@B25] \[G^L^\]                                                                                                                                    
  MUC5AC                               Mucin 5AC                               Bronchoscopy tissue sample, Left lung tissue          Mouse          G^HL^          Laprise et al., [@B28] \[G^H^\]
  Park et al., [@B42] \[G^H^\]                                                                                                                                     
  Ordonez et al., [@B41] \[G^L^\]                                                                                                                                  
  NOS2A                                Nitric oxide synthase                   Bronchoscopy tissue sample                            Mouse          G^HL^, E^L^    Laprise et al., [@B28] \[G^H^\]
  Torrone et al., [@B53] \[E\]                                                                                                                                     
  Pascual et al., [@B43] \[G^L^\]                                                                                                                                  
  Retnla                               Resistin like alpha                     Lung eosinophil, BAL macrophage                       Mouse          G^HL^          Siddiqui et al., [@B47] \[G^H^\]
  Tumes et al., [@B54] \[G^H^\]                                                                                                                                    
  Doherty et al., [@B9] \[G^L^\]                                                                                                                                   
  SERPINB                              Serpin peptidase inhibitor, clade B     Bronchoscopy tissue sample, airway epithelial cells   Human, mouse   G^HL^          Woodruff et al., [@B56] \[G^H^\]
  Laprise et al., [@B28] \[G^H^\]                                                                                                                                  
  Karaaslan et al., [@B25a] \[G^L^\]                                                                                                                               
  S100A9                               Calcium binding protein A9              CD3+T cell                                            Human          P^HL^          Wu et al., [@B57] \[P^H^\]
  Jeong et al., [@B23] \[P^H^\]                                                                                                                                    
  Lee et al., [@B29] \[P^L^\]                                                                                                                                      

G, Genomics; P, Proteomics; E, Epigenetics; BAL, Broncho alveolar lavage; H, High-throughput; L, Low-throughput.

In genomic studies of asthma several genes have been found to be significantly induced, of which some significant biomarkers are Chemokine ligands (CCL8, CCL5, CCL11, and CCL24), SERPINs (SERPINB2, SERPINB4, and SERPINA1) and CarboxypeptidaseA3. These three genes have not been studied earlier in detail however they have the potential of being used as asthma biomarkers. Chemokine ligands are potent attractants of Th2 lymphocytes at the site of lung inflammation in atopic asthma (Lukacs, [@B34]). SERPINS are members serine protease inhibitors family which inhibit neutrophil protease cathepsin G and mast cell chymase and protects the lower respiratory tract from damage caused by proteolytic enzymes. Thus, it can be used as potent diagnostic marker of asthma attack (Zou et al., [@B62]). Carboxypeptidase A3 is an asthma associated protease identified in lung epithelium and is a significant mast cell marker and was found to be upregulated in 42 non-smoking asthma patients (Woodruff et al., [@B56]). Retnla, also known as Fizz (found in inflammatory zone) protein is an inducible product of bronchial epithelial cell. This is considered as a marker of alternatively activated macrophages and highly polarized Th2 responses. In Retnla deficient mice the severity of atopic response is increased dramatically, whereas the IL13 response is suppressed by Retnla in airway hyper-responsiveness (Pesce et al., [@B44]). NOS2A is a gene that encodes inducible nitric oxide synthase, iNOS which produce nitric oxide (NO) from T lymphocytes in response to proinflammatory cytokines in an asthma model (Ricciardolo et al., [@B45]). This NO assists in the development of reactive nitrogen species such as peroxynitrites leading to cellular injury in the airways (Gabazza et al., [@B13]). NOS2A was found to be upregulated in bronchial biopsies in a microarray study (Laprise et al., [@B28]) and a (CCTTT)~n~ polymorphism in the promoter region was associated with asthma phenotype studied in White population (Pascual et al., [@B43]) and some SNP\'s were found on asthmatic children having Latino and Caucasian ancestry (Islam et al., [@B21]). These genes together with other mediators contribute to epithelial cell activation and dysfunction (Dougherty et al., [@B10]).

Proteomic approach
------------------

Proteomic approaches are widely used to identify the expression level and modification of proteins to understand the pathophysiology of asthma. Proteomic signatures of lung parenchyma, BAL fluid, Immune cells (CD3+T cells or CD4+ T cells) from human or animal model have been used in different studies after experimental allergen challenge or after natural exposure to inhalant allergens. The advancement of proteomic techniques from earlier 2D gel based approach to recently more advanced LC-MS/MS based analysis resulted in precise identification of candidate proteins involved in asthma inflammation. In Table [1](#T1){ref-type="table"} we have listed six proteins identified in asthma proteomics studies, which can be analyzed in more detail to use them as clinical biomarkers. Similarly in asthma proteomics, a number of protein biomarkers have been identified, three of these potential biomarkers include AMcase (Chia, Chi3l3, Chi3l4, Chi3l1, and ChiT1), Calcium binding protein (S100A8 and S100A9), and Arginase (Arg1 and Arg2). These three proteins and their corresponding genes need further investigation at system level to reveal their use as potential diagnostic biomarkers.

AMcases are human chitinases induced via Th2 specific IL13 mediated pathway in aeroallergen challenged lung epithelium and macrophages as means of host defense. Th2 inflammation in asthma can be improved by targeted neutralization of these human chitinases (Zhu et al., [@B60]). A K(Lys)17R(Arg) polymorphism was identified in AMcase gene by genotyping study conducted on 322 pediatric asthma patients at University of Berlin and Freiburg (Bierbaum et al., [@B3]). Chi3l3 (Ym1) and Chi3l4 (Ym2) are other non-chitinolytic chitin binding proteins, have close linkage with asthma. Certain corticosteroids and leukotrienes receptor antagonist were shown to suppress the elevated pulmonary level of this protein (Zhu et al., [@B60]).

Calcium binding protein (S100A9/A8) form complex and inhibits macrophage activation and immunoglobulin synthesis by lymphocytes. Its homodimer also acts as a chemotactic agent for leukocytes and has pro-inflammatory activity on endothelial cell and inflammatory cells (Zhou et al., [@B59]). It is found in neutrophil cytoplasm and released upon cell activation (Cookson, [@B7]). This protein was found to be highly upregulated in endotoxin mediated response in non-smoking population challenged with endotoxin (Michel et al., [@B37]).

In asthmatic lung, Arginase expression is increased via Th2-induced, STAT6-dependent mechanism (Zimmermann et al., [@B61]). This affects arginine metabolism, and contribute to asthma pathogenesis through inhibition of NO generation and alterations of cell growth and collagen deposition (Shi et al., [@B46]). Association between four SNP\'s in this gene and atopic asthma were identified by genotyping 433 asthmatic case-parent triads in a public hospital of Mexican city (Huiling et al., [@B20]).

BPIFA1 (also known as SPLUNC), is highly expressed in the upper airways and nasopharyngeal regions and thought to be involved in inflammatory responses to irritants in the upper airways (Barnes et al., [@B2]). A Sialylated form of BPIFA1 was observed as post translational modification and was identified as being predominant in nasal lavage fluid (NLF) of allergy rhinitis patients (Ghafouri et al., [@B15]).

Epigenomic approach
-------------------

Epigenomics has emerged as a promising field, and have addressed the gaps in our current understanding of the interaction between nature and nurture in the development of asthma. Epigenetic modification can alter the DNA structure (by methylation, acetylation), the chromatin structure (by altering the Scaffolding protein) and by small non-coding RNAs. It was found that reduced Histone Deacetylase (HDAC) activity and increased Histone acetyl transferase (HAT) activity jointly promotes the expression of multiple inflammatory genes associated with asthma, however inhaled steroids reduce HAT activity to the normal level (Ito et al., [@B22]). External stimuli such as allergen exposure, cigarette smoke, traffic exhaust and folate rich diet cause methylation mediated silencing of genes like IFNγ, Fox-P3, IL2, iNOS and hypomethylation mediated activation of genes like IL6, IL4, IL8, and Acyl CoA thus increasing the Th2 phenotype assisting in the development of asthma (Durham et al., [@B11]). Usually IFN-γ and FOX-P3 undergo H4 acetylation and demethylation mediated activation to prevent post natal asthma and *in-utero* atopicity, respectively (Lovinsky-Desir and Miller, [@B32]). In the promoter region and other cis-acting element of two important Th2 cytokines like IL4 and IL13 demethylation causes recruitment of STAT6 and GATA3 thereby enhancing their expression (Miller and Ho, [@B38]). In addition to that small non-coding RNA plays a crucial role in fine epigenetic tuning of genes which are key factors in asthma pathophysiology (Durham et al., [@B11]). These include let-7, miR-9, miR-21, miR-125, miR-146a, miR-147, and miR-155. For example let-7 families of micro RNA and mi R-155 are found to inhibit expression of IL 13. This miRNA was found to block the IL13 R alpha 1 and ultimately lower the expression of STAT 6 thus controlling the Th2/Th1 balance in macrophages (Kumar et al., [@B26] and Martinez-Nunez et al., [@B36]). An overexpression of miR21 and an underexpression of miR1 were demonstrated in IL-13 induced transgenic mice. This miR-21 was also found to control expression of IL12, a molecule responsible for Th2 mediated cellular response (Lu et al., [@B33]). A G/C polymorphism in miRNA146a gene locus resulted in a functional variant that in turn can significantly modulate expression of genes such as TNF-α, IL-6, Cox-2, iNOS, and RANTES that are closely linked with asthma pathophysiology (Jiménez-Morales et al., [@B24]). This polymorphism was found to have statistically significant association with a pediatric Mexican cohort.

### Integrated approaches

We have compiled the asthma biomarkers from different approaches including genomics, proteomics and epigenetics and have found little overlap amongst them as shown in Figure [1A](#F1){ref-type="fig"}. Detailed molecular information of all asthma related biomarkers are stored in DAAB. All the genes compiled from the high-throughput experiments have significant value (*p* = 0.05) of fold change, validated further by low-throughput techniques such as PCR, blotting and hold significantly close association with asthma pathophysiology.

![**(A)** Venn diagram showing asthma biomarkers identified in three different approaches of Genomics \[G\], Proteomics \[P\] and Epigenetic \[E\] studies with overlaps among the intersects. **(B)** Significant pathways; **(C)** enriched gene ontology molecular functions, and **(D)** biological function terms are listed which are linked with asthma biomarkers (Pathway and Gene Ontology analyses were done using Pathway studio 7.1[^2^](#fn0002){ref-type="fn"}, Ariadane Genomics, Rockville, MD, USA). Pathways are significant where (−log~10~P) ≥ 1.3 (0.05% significance).](fgene-04-00308-g0001){#F1}

Furthermore, we have listed fifteen genes in Table [1](#T1){ref-type="table"}, which have been cited for two or more times in DAAB database. Asthma is dependent on many factors and thus it develops as a consequence of crosstalk among different pathways. Thus, we analyzed all the genes in our dataset compiled from several literatures in order to identify the pathways containing these biomarkers. Figure [1B](#F1){ref-type="fig"} shows cytokine pathways, ROS metabolism, NO metabolism and certain other metabolic pathways were significantly enriched (Detailed information of Figure [1B](#F1){ref-type="fig"} is shown in Table [A1](#TA1){ref-type="table"}). In addition, Gene ontology of the biomarkers is shown in Figures [1C,D](#F1){ref-type="fig"} (Detailed information of GO terms are shown in Tables [A2](#TA2){ref-type="table"}, [A3](#TA3){ref-type="table"}). Cytokine activity, growth factor activity and Arginase activity were found to be significantly enriched in molecular function analysis. With respect to biological process inflammatory response, immune response and cell proliferation were found to be considerably predominating.

The most significant pathway triggering asthma has been the adipocyte signaling pathway. A few significant genes such as ACSL3, IL13, IL9, IL4, IL2, IL10, IFNA1, SOCS1, PON1, APOB, SOCS3, SCD, and NR1D1 were found to be the component of this pathway and associated with asthma pathogenesis (Tilg and Moschen, [@B51]; Diego et al., [@B8]). Adipokine or adipocytokine are cytokines secreted by the adipose tissues. These include Th2 cytokines and chemokines such as MCP1, RANTES, which are potent attractants of mast cells. There are also several clinical observations suggesting the role of obesity with asthma and one of the major conclusions so far has been the action of adipocytes derived cytokines which inhibit the activity of T-regs thus decreasing the tolerance (Theoharides et al., [@B50]). Cytokines such as TNFα, IL6 secreted by the adipocytes are important mediators of asthma. These molecules also affect vascular function by modulating nitric oxide and superoxide release. Some molecules such as leptin, adiponectin are the most abundantly expressed adipocytokines and are involved in classical cytokine pathway thus showing an asthmatic phenotype (Guzik et al., [@B18]).

Another significant pathway has been the ROS signaling pathway which is characterized by production of free radicals from molecular oxygen due to recruitment of activated inflammatory cells and associated with mitochondrial dysfunction that result in variety of physiological changes including increased airway reactivity, tissue injury and mucus production (Zuo and Clanton, [@B63]). Presently certain metabolites such as malondialdehyde, 8-isoprostane, exhaled NO, thiobarbituric acid are used as markers to measure the disease severity in sputum or exhaled air (Zuo et al., [@B64]). Several genes including MPO, PRDX6, SOD1, and CYBB as molecules involved in asthmatic responses and linked to ROS generation and hold the potential of using as biomarkers.

An additional significant pathway uncovered has been the Urea cycle and arginine metabolism. iNOS, ARG1, and ARG2 belong to this pathway and have also been found to be induced significantly in several genomic, proteomic, and epigenetic studies (North et al., [@B40]; Breton et al., [@B4]; Cloots et al., [@B6]). In asthmatic airway inducible NOS in inflammatory cells catalyses the production of NO from L-arginine, which results in the formation of reactive nitrogen species (RNS) that alters protein function by nitration of tyrosine residues thereby mediating inflammation and injury. In asthmatics upregulation of Arginase limits the availability of L-arg to iNOS thus generating peroxynitrite and concomitant nitration of proteins. It also enhances the level of L-ornithine which promotes airway remodeling by collagen deposition and excess cell proliferation (Ghosh and Erzurum, [@B16]).

Conclusion {#s2}
==========

In the last few decades efforts to understand the pathophysiogy of allergic asthma has been intensified to a great extent because of increased mortality and morbidity. The aim of the present review is to focus on genes or their products which can be used as biomarker for allergic asthma. Occurrence of allergic asthma involves multiple genes, environmental factors and epigenetic mechanisms. Presently the potential difficulties to diagnose this disease are due to (i) remarkable overlap in symptoms of other pulmonary diseases, (ii) high interindividual and interpopulation variation at genetic level leads to changes in the uniformity of molecular marker, and (iii) absence of discriminative molecular markers, specific to atopic asthma, since most of the biomarkers currently used or in clinical trial are indicative of asthmatic inflammation irrespective of atopic background. Some of the common features of asthma exacerbation are eosinophilic inflammation, collagenitis, mucus deposition and extracellular matrix formation. However, these are common characteristics of other lung inflammations such as Chronic Obstructive Pulmonary Disease (COPD) or, non-allergic asthma. Therefore, the genes involved in these phenotypes may also be induced in all kinds of lung inflammations. To develop diagnostic markers exclusively for "allergic asthma" it is necessary to identify upstream components of the molecular pathways initiated immediately after allergen sensitization. Researchers can use these biomarkers for screening and risk assessment before the disease assumes severity by (i) identifying polymorphisms in wide population and (ii) correlating them with the alteration of signaling pathways that ultimately lead to allergic asthma. Since application of single biomarker approach to asthma research may not be realistic, newly identified biomarkers can be integrated in a multidimensional way to strengthen the treatment. Our mini review is focused on biomarker discovery by systemic approach using high-throughput "OMICS" platforms including genomics, proteomics and epigenetics and further some of them are well-studied in low-throughput experiments. Application of systems biology as a discipline provides a way to investigate the pathophysiology of asthma by giving a closer look to the system components, its dynamics and response to any kind of perturbation in the population level. Systemic approaches may emerge as a promising strategy to zoom into the global mechanism and identify features specific to asthma for developing better diagnostics and therapeutics.
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###### 

**The list of pathways that play key role in asthma pathogenesis, as evident from the biomarkers identified by genomics, proteomics and epigenomics approaches**.

  **Name of the pathway**                          **Total entities**   **Expanded of entities**   **Overlap**   **Percent overlap**   **Overlapping entities**                                                          ***p*-value**   **(−log*P*)**
  ------------------------------------------------ -------------------- -------------------------- ------------- --------------------- --------------------------------------------------------------------------------- --------------- ---------------
  Adipocytokine signaling                          52                   780                        13            1                     ACSL3, IL13, IL9, IL4, IL2, IL10, IFNA1, SOCS1, PON1, APOB, SOCS3, SCD, NR1D1     0.001809        2.742605
  ROS metabolism                                   43                   74                         3             4                     PRDX6, SOD1, CYBB                                                                 0.004493        2.347436
  ActivinR -\> SMAD2/3 signaling                   23                   23                         2             8                     INHBA, INHA                                                                       0.010913        1.962064
  Urea cycle and arginine metabolism               86                   110                        3             2                     NOS2A, ARG1, ARG2                                                                 0.013536        1.868503
  Translation control                              86                   984                        13            1                     CCL11, EGFR, IL13, IL9, IL4, IL2, IL10, CCL21, IFNA1, SOCS1, VEGFC, SOCS3, GNB2   0.013549        1.86809
  ActivinR/BMPR -\> SMAD1/5/9 signaling            27                   27                         2             7                     INHBA, INHA                                                                       0.014876        1.827505
  Apoptosis regulation                             69                   613                        9             1                     IL13, IL9, IL4, TGFB1, IL2, IL10, IFNA1, INHBA, INHA                              0.022869        1.640747
  Mast cell activation                             64                   529                        8             1                     PTGS2, IL13, IL9, IL4, IL2, IL10, IFNA1, ALOX15                                   0.027347        1.563092
  Skeletal myogenesis control                      70                   569                        8             1                     EGFR, TGFB1, SOCS1, INHBA, CYBB, VEGFC, INHA, SOCS3                               0.039923        1.39878
  NK Cell Activation                               59                   523                        7             1                     IL13, IL9, IL4, IL2, IL10, IFNA1, TYROBP                                          0.067085        1.173375
  EDG2 -\> ELK-SRF signaling                       33                   78                         2             2                     EGFR, GNB2                                                                        0.102033        0.991259
  T cell activation                                81                   1100                       11            1                     SGPP1, PTGS2, IL13, IL9, IL4, IL2, IL10, CTLA4, IFNA1, ALOX15, CNN1               0.129288        0.888442
  GFR -\> FOXO3A signaling                         7                    94                         2             2                     EGFR, VEGFC                                                                       0.138723        0.857852
  DopamineR2 -\> AP-1/CREB/ELK-SRF signaling       47                   95                         2             2                     EGFR, GNB2                                                                        0.141106        0.850455
  CholinergicRm -\> CREB/ELK-SRF signaling         41                   107                        2             1                     EGFR, GNB2                                                                        0.170351        0.768655
  GRM1/5 -\> CREB signaling                        39                   110                        2             1                     EGFR, GNB2                                                                        0.177823        0.750012
  Melanogenesis                                    51                   682                        7             1                     INMT, CCL11, EGFR, CCL21, PRDX6, VEGFC, GNB2                                      0.190612        0.71985
  Adherens junction regulation                     41                   692                        7             1                     EGFR, TGFB1, INHBA, VEGFC, CDH11, INHA, DSP                                       0.20054         0.697799
  GFR -\> NCOR2 signaling                          27                   130                        2             1                     EGFR, VEGFC                                                                       0.228743        0.640652
  GFR -\> AP-1/CREB/CREBBP/ELK-SRF/MYC signaling   50                   156                        2             1                     EGFR, VEGFC                                                                       0.296227        0.528375

*The data was generated using Pathway studio 7.1, Ariadane Genomics, Rockville, MD, USA. The column names are: Name of the pathway; Total entities; expanded entities; overlap; percent overlap; overlapping entities; p-value and −log~10~ p-value*.

###### 

**The list of Gene Ontology Molecular Function (GOMF) terms that are significant in asthma pathogenesis, as evident from the biomarkers identified by genomics, proteomics and epigenomics approaches**.

  **Name of the GOMF terms**                                                                  **Total entities**   **Expanded number of entities**   **Overlap**   **Percent overlap**   **Overlapping entities**                                                                                                                                                                                                                                                                  ***p*-value**   **(−log*P*)**
  ------------------------------------------------------------------------------------------- -------------------- --------------------------------- ------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ---------------
  Cytokine activity                                                                           217                  217                               13            5                     Ccl8, Cxcl15, CCL11, IL13, IL9, IL4, IL2, IL10, CCL21, IFNA1, INHBA, INHA, SCGB3A1                                                                                                                                                                                                        3.30E--13       12.48204
  Growth factor activity                                                                      198                  198                               8             4                     IL9, IL4, TGFB1, IL2, INHBA, VEGFC, INHA, TFF2                                                                                                                                                                                                                                            3.10E--07       6.509308
  Arginase activity                                                                           2                    2                                 2             100                   ARG1, ARG2                                                                                                                                                                                                                                                                                1.08E--05       4.967132
  Hematopoietin-interferon-class (D200-domain) cytokine receptor binding                      47                   47                                4             8                     IL13, IL9, IL4, IFNA1                                                                                                                                                                                                                                                                     1.78E--05       4.750718
  Chemokine activity                                                                          56                   56                                4             7                     Ccl8, Cxcl15, CCL11, CCL21                                                                                                                                                                                                                                                                3.57E--05       4.446842
  Protein binding                                                                             7274                 7274                              41            0                     Muc5ac, Serpinb3c, Apoa1, ACSL3, Igh-6, IGHG1, PTGS2, EGFR, ORM1, IL13, IL4, TGFB1, IL2, IL10, CTLA4, NOS2A, SERPINA1, SOCS1, SOD1, ARG2, APOB, CYBB, TIMP4, FCGR2B, POSTN, FOXP3, CDH11, INHA, S100A9, SOCS3, TYROBP, VIM, TCF21, FBN1, C4BPA, AATF, SCNN1G, HSPA1B, ITIH1, LCN1, GNB2   7.37E--05       4.132694
  Protein heterodimerization activity                                                         268                  268                               6             2                     EGFR, TGFB1, INHBA, APOB, CYBB, INHA                                                                                                                                                                                                                                                      0.000265        3.576101
  Metallopeptidase activity                                                                   178                  178                               5             2                     CPA4, MMP12, ADAM33, ACE, ADAM8                                                                                                                                                                                                                                                           0.000314        3.502791
  Complement binding                                                                          9                    9                                 2             22                    CFB, C4BPA                                                                                                                                                                                                                                                                                0.000383        3.417369
  Chitinase activity                                                                          11                   11                                2             18                    Chi3l3, CHIA                                                                                                                                                                                                                                                                              0.000582        3.235176
  High-density lipoprotein binding                                                            11                   11                                2             18                    Apoa1, PON1                                                                                                                                                                                                                                                                               0.000582        3.235176
  Hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amidines   11                   11                                2             18                    ARG1,ARG2                                                                                                                                                                                                                                                                                 0.000582        3.235176
  Endopeptidase inhibitor activity                                                            118                  118                               4             3                     SERPINA1, SERPINB2, CSTA, ITIH1                                                                                                                                                                                                                                                           0.000639        3.194323
  Protein binding, bridging                                                                   60                   60                                3             5                     DSP, CSTA, COL11A1                                                                                                                                                                                                                                                                        0.001039        2.983192
  Peptidase activity                                                                          633                  633                               8             1                     Slpi, CPA4, MMP12, SERPINA1, ADAM33, ACE, CFB, ADAM8                                                                                                                                                                                                                                      0.001171        2.93128
  Phospholipid binding                                                                        64                   64                                3             4                     Apoa1, PON1, APOB                                                                                                                                                                                                                                                                         0.001254        2.901838
  Cholesterol transporter activity                                                            16                   16                                2             12                    Apoa1, APOB                                                                                                                                                                                                                                                                               0.001256        2.901021
  Serine-type endopeptidase inhibitor activity                                                150                  150                               4             2                     Serpinb3c, SERPINA1, SERPINB2, ITIH1                                                                                                                                                                                                                                                      0.001558        2.807388
  Antioxidant activity                                                                        20                   20                                2             10                    PRDX6, SOD1                                                                                                                                                                                                                                                                               0.001972        2.705175
  Antigen binding                                                                             79                   79                                3             3                     Igh-2, Igh-6, IGHG1                                                                                                                                                                                                                                                                       0.002296        2.63899

The data was generated using Pathway studio 7.1, Ariadane Genomics, Rockville, MD, USA. The column names are: Name of the GOMF terms; Total entities; expanded entities; overlap; percent overlap; overlapping entities; p-value and −log~10~ p-value.

###### 

**The list of Gene Ontology Biological Process (GOBP) terms that are significant in asthma pathogenesis, as evident from the biomarkers identified by genomics, proteomics and epigenomics approaches**.

  **Name of GOBP terms**                                          **Total entities**   **Expanded number of entities**   **Overlap**   **Percent overlap**   **Overlapping entities**                                                                                ***p*-value**   **(−log*P*)**
  --------------------------------------------------------------- -------------------- --------------------------------- ------------- --------------------- ------------------------------------------------------------------------------------------------------- --------------- ---------------
  Inflammatory response                                           293                  15                                5             5                     Ccl8, Cxcl15, CCL11, PTGS2, ORM1, IL13, IL9, IL4, TGFB1, IL10, NOS2A, CCL21, CYBB, ALOX15, S100A9       4.54E--15       14.34325
  Immune response                                                 604                  16                                2             2                     LILRA6, Ccl8, Cxcl15, IGHG1, CCL11, IL13, IL9, IL4, IL2, IL10, CTLA4, CCL21, FCGR2B, CFB, C4BPA, CHIA   1.24E--11       10.90786
  Negative regulation of immune response                          14                   4                                 28            28                    TGFB1, CTLA4, FCGR2B, FOXP3                                                                             5.90E--08       7.229314
  Negative regulation of interferon-gamma biosynthetic process    4                    3                                 75            75                    INHBA, FOXP3, INHA                                                                                      8.79E--08       7.055796
  Anti-apoptosis                                                  198                  8                                 4             4                     IL2, IL10, SOD1, ALOX15, SOCS3, SERPINB2, AATF, HSPA1B                                                  9.69E--08       7.013485
  Regulation of cell proliferation                                135                  7                                 5             5                     PTGS2, EGFR, TGFB1, NOS2A, ADAM33, INHA, SCGB3A1                                                        1.18E--07       6.929752
  Response to drug                                                295                  9                                 3             3                     Apoa1, PTGS2, MMP12, TGFB1, SOCS1, SOD1, CYBB, TIMP4, SOCS3                                             1.62E--07       6.791126
  Positive regulation of B cell proliferation                     23                   4                                 17            17                    Igh-6, IL13, IL4, IL2                                                                                   5.12E--07       6.290996
  Negative regulation of T cell proliferation                     26                   4                                 15            15                    TGFB1, IL10, CTLA4, FOXP3                                                                               8.58E--07       6.066354
  Response to cytokine stimulus                                   77                   5                                 6             6                     PTGS2, SERPINA1, SOCS1, TIMP4, SOCS3                                                                    2.73E--06       5.563052
  Response to estradiol stimulus                                  79                   5                                 6             6                     PTGS2, TGFB1, ERPINA1, SOCS1, SOCS3                                                                     3.11E--06       5.50781
  Skeletal system development                                     147                  6                                 4             4                     TGFB1, INHBA, POSTN, CDH11, INHA, FBN1                                                                  3.98E--06       5.400395
  Positive regulation of epithelial cell proliferation            44                   4                                 9             9                     EGFR, MMP12, TGFB1, VEGFC                                                                               7.50E--06       5.125108
  Response to lipopolysaccharide                                  99                   5                                 5             5                     PTGS2, SERPINA1, SOCS1, TIMP4, SOCS3                                                                    9.43E--06       5.025503
  Organ regeneration                                              49                   4                                 8             8                     Apoa1, TGFB1, SOCS1, SOCS3                                                                              1.16E--05       4.936449
  Cell--cell signaling                                            275                  7                                 2             2                     IL13, IL2, IL10, CCL21, INHBA, INHA, S100A9                                                             1.35E--05       4.869351
  Response to hypoxia                                             184                  6                                 3             3                     TGFB1, NOS2A, SERPINA1, ACE, SOCS3, SCNN1G                                                              1.44E--05       4.842389
  Positive regulation of folliclE-stimulating hormone secretion   3                    2                                 66            66                    INHBA, INHA                                                                                             2.38E--05       4.62283
  Positive regulation of regulatory T cell differentiation        3                    2                                 66            66                    IL2, FOXP3                                                                                              2.38E--05       4.62283
  Response to external stimulus                                   23                   3                                 13            13                    INHBA, PON1, INHA                                                                                       3.75E--05       4.426548

The data was generated using Pathway studio 7.1, Ariadane Genomics, Rockville, MD, USA. The column names are: Name of the GOBP terms; Total entities; expanded entities; overlap; percent overlap; overlapping entities; p-value and −log~10~ p-value.
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